Mary E Charlton1, Amanda R Kahl1, Alissa A Greenbaum2, Jordan J Karlitz3, Chi Lin4, Charles F Lynch1, Vivien W Chen5. 1. Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa 2. Department of Surgery, School of Medicine, University of New Mexico, Albuquerque, New Mexico 3. Division of Gastroenterology, School of Medicine, Tulane University, New Orleans, Louisiana 4. Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, Nebraska 5. Louisiana Tumor Registry and Epidemiology Program, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, Louisiana
Abstract
Purpose:KRAS mutations and tumor location have been associated with response to targeted therapy among patients with stage IV colorectal cancer (CRC) in various trials. This study performed the first population-based examination of associations between KRAS mutations, tumor location, and survival, and assessed factors associated with documented KRAS testing. Methods: Patients with stage IV adenocarcinoma of the colon/rectum diagnosed from 2010 to 2013 were extracted from SEER data. Analyses of patient characteristics, KRAS testing, and tumor location were conducted using logistic regression. Cox proportional hazards models assessed relationships between KRAS mutations, tumor location, and risk of all-cause death. Results: Of 22,542 patients, 30% received KRAS testing, and 44% of these had mutations. Those tested tended to be younger, married, and metropolitan area residents, and have private insurance or Medicare. Rates of KRAS testing also varied by registry (range, 20%-46%). Patients with right-sided colon cancer (vs left-sided) tended to be older, female, and black; have mucinous, KRAS-mutant tumors; and have a greater risk of death (hazard ratio [HR], 1.27; 95% CI, 1.22-1.32). KRAS mutations were not associated with greater risk of death in the overall population; however, they were associated with greater risk of death among patients with left-sided colon cancer (HR, 1.19; 95% CI, 1.05-1.33). Conclusions: This large population-based study showed that among patients initially diagnosed with stage IV CRC, right-sided colon cancer was associated with greater risk of death compared with left-sided cancer, and KRAS mutations were only associated with risk of death in left-sided colon cancer. An unexpected finding was that among patients with stage IV disease, right-sided cancer was more commonly seen in black patients versus whites. Future studies should further explore these associations and determine the role of biology versus treatment differences. In addition, use of KRAS testing is increasing, but there is wide geographic variation wherein disparities related to insurance coverage and rurality may warrant further study.
Purpose:KRAS mutations and tumor location have been associated with response to targeted therapy among patients with stage IV colorectal cancer (CRC) in various trials. This study performed the first population-based examination of associations between KRAS mutations, tumor location, and survival, and assessed factors associated with documented KRAS testing. Methods:Patients with stage IV adenocarcinoma of the colon/rectum diagnosed from 2010 to 2013 were extracted from SEER data. Analyses of patient characteristics, KRAS testing, and tumor location were conducted using logistic regression. Cox proportional hazards models assessed relationships between KRAS mutations, tumor location, and risk of all-cause death. Results: Of 22,542 patients, 30% received KRAS testing, and 44% of these had mutations. Those tested tended to be younger, married, and metropolitan area residents, and have private insurance or Medicare. Rates of KRAS testing also varied by registry (range, 20%-46%). Patients with right-sided colon cancer (vs left-sided) tended to be older, female, and black; have mucinous, KRAS-mutant tumors; and have a greater risk of death (hazard ratio [HR], 1.27; 95% CI, 1.22-1.32). KRAS mutations were not associated with greater risk of death in the overall population; however, they were associated with greater risk of death among patients with left-sided colon cancer (HR, 1.19; 95% CI, 1.05-1.33). Conclusions: This large population-based study showed that among patients initially diagnosed with stage IV CRC, right-sided colon cancer was associated with greater risk of death compared with left-sided cancer, and KRAS mutations were only associated with risk of death in left-sided colon cancer. An unexpected finding was that among patients with stage IV disease, right-sided cancer was more commonly seen in black patients versus whites. Future studies should further explore these associations and determine the role of biology versus treatment differences. In addition, use of KRAS testing is increasing, but there is wide geographic variation wherein disparities related to insurance coverage and rurality may warrant further study.
Authors: Paul F Engstrom; Juan Pablo Arnoletti; Al B Benson; Yi-Jen Chen; Michael A Choti; Harry S Cooper; Anne Covey; Raza A Dilawari; Dayna S Early; Peter C Enzinger; Marwan G Fakih; James Fleshman; Charles Fuchs; Jean L Grem; Krystyna Kiel; James A Knol; Lucille A Leong; Edward Lin; Mary F Mulcahy; Sujata Rao; David P Ryan; Leonard Saltz; David Shibata; John M Skibber; Constantinos Sofocleous; James Thomas; Alan P Venook; Christopher Willett Journal: J Natl Compr Canc Netw Date: 2009-09 Impact factor: 11.908
Authors: Paul F Engstrom; Juan Pablo Arnoletti; Al B Benson; Yi-Jen Chen; Michael A Choti; Harry S Cooper; Anne Covey; Raza A Dilawari; Dayna S Early; Peter C Enzinger; Marwan G Fakih; James Fleshman; Charles Fuchs; Jean L Grem; Krystyna Kiel; James A Knol; Lucille A Leong; Edward Lin; Mary F Mulcahy; Sujata Rao; David P Ryan; Leonard Saltz; David Shibata; John M Skibber; Constantinos Sofocleous; James Thomas; Alan P Venook; Christopher Willett Journal: J Natl Compr Canc Netw Date: 2009-09 Impact factor: 11.908
Authors: S Y Brulé; D J Jonker; C S Karapetis; C J O'Callaghan; M J Moore; R Wong; N C Tebbutt; Cr Underhill; D Yip; J R Zalcberg; D Tu; R A Goodwin Journal: Eur J Cancer Date: 2015-05-12 Impact factor: 9.162
Authors: Veena Shankaran; Jesse D Ortendahl; Anna G Purdum; Bjorn Bolinder; Ayanna M Anene; Gordon H Sun; Tanya G K Bentley Journal: Am J Clin Oncol Date: 2018-01 Impact factor: 2.339
Authors: Fotios Loupakis; Dongyun Yang; Linda Yau; Shibao Feng; Chiara Cremolini; Wu Zhang; Martin K H Maus; Carlotta Antoniotti; Christiane Langer; Stefan J Scherer; Thomas Müller; Herbert I Hurwitz; Leonard Saltz; Alfredo Falcone; Heinz-Josef Lenz Journal: J Natl Cancer Inst Date: 2015-02-24 Impact factor: 13.506
Authors: Robert A Meguid; Mark B Slidell; Christopher L Wolfgang; David C Chang; Nita Ahuja Journal: Ann Surg Oncol Date: 2008-07-12 Impact factor: 5.344
Authors: Joanna H M Tong; Raymond W M Lung; Frankie M C Sin; Peggy P Y Law; Wei Kang; Anthony W H Chan; Brigette B Y Ma; Tony W C Mak; Simon S M Ng; Ka Fai To Journal: Cancer Biol Ther Date: 2014-03-18 Impact factor: 4.742
Authors: Maria Hernandez-Ainsa; Raul Velamazan; Angel Lanas; Patricia Carrera-Lasfuentes; Elena Piazuelo Journal: Front Med (Lausanne) Date: 2022-06-20
Authors: Paolo Goffredo; Alan F Utria; Anna C Beck; Yun Shin Chun; James R Howe; Ronald J Weigel; Jean-Nicolas Vauthey; Imran Hassan Journal: J Gastrointest Surg Date: 2018-10-01 Impact factor: 3.452
Authors: Daniel J Becker; Kyung M Lee; Steve Y Lee; Kristine E Lynch; Danil V Makarov; Scott E Sherman; Christy D Morrissey; Michael J Kelley; Julie A Lynch Journal: JCO Precis Oncol Date: 2021-04-13